STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Clinical trials for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy drug may save eyes from advanced skin cancer
Disease control Recruiting nowThis study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this type of cancer will receive the drug. The goal is to see if the treatment can reduce tumors and help patients keep their e…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis study tests if adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 adults will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to see if BMX-001 helps prevent painf…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 20, 2026 11:55 UTC